ClinicalTrials.gg
CompletedNCT02321800APEKS-cUTIUpdated Dec 12, 2019Results posted

A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections

A Phase 2 interventional study of Cefiderocol and Imipenem/cilastatin in Urinary Tract Infections, sponsored by Shionogi. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-12.

Sponsored by Shionogi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
452
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study was to determine the efficacy and safety of intravenous cefiderocol (S-649266) in hospitalized adults with complicated urinary tract infections caused by Gram-negative pathogens.

02

Conditions studied

  • Urinary Tract Infections

Keywords

  • S-649266
  • complicated urinary tract infection
  • cefiderocol
  • acute uncomplicated pyelonephritis
  • Gram-negative pathogens
  • imipenem/cilastatin
03

In context

Urinary Tract Infections

806 studies on the registry are indexed under Urinary Tract Infections; 134 are open to participants now.

This study's enrollment of 452 is above the median of 133 across 562 interventional studies indexed under Urinary Tract Infections.

Browse Urinary Tract Infections studies →

Lead sponsor

Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.

Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized male and female patients ≥ 18 years
  • Clinical diagnosis of either complicated urinary tract infections (cUTI) with or without pyelonephritis or acute uncomplicated pyelonephritis
  • cUTI diagnosed with a history of ≥ 1 of the following:

    • Indwelling urinary catheter or recent instrumentation of the urinary tract
    • Urinary retention (caused by benign prostatic hypertrophy)
    • Urinary retention of at least 100 mL or more of residual urine after voiding (neurogenic bladder)
    • Obstructive uropathy
    • Azotemia caused by intrinsic renal disease (blood urea nitrogen and creatinine values greater than normal laboratory values) OR Pyelonephritis and normal urinary tract anatomy, ie, acute uncomplicated pyelonephritis AND

At least 2 of the following signs or symptoms:

  • Chills or rigors or warmth associated with fever (temperature greater than or equal to 38 degrees Celsius)
  • Flank pain (pyelonephritis) or suprapubic/pelvic pain (cUTI)
  • Nausea or vomiting
  • Dysuria, urinary frequency, or urinary urgency
  • Costo-vertebral angle tenderness on physical examination AND

All subjects had to have urinalysis evidence of pyuria demonstrated by 1 of the following:

  • Dipstick analysis positive for leukocyte esterase
  • ≥ 10 white blood cells (WBCs) per μL in unspun urine, or ≥ 10 WBCs per high power field in spun urine

    • Positive urine culture within 48 hours prior to randomization containing ≥10\^5 colony forming unit (CFU)/mL of a Gram-negative uropathogen likely to be susceptible to imipenem (IPM)
    • Patients who were treated previously with an empiric antibiotic other than the study drugs but failed treatment, both clinically and microbiologically, were eligible for the study if they had an identified Gram-negative uropathogen that was not susceptible to the previously used empiric treatment and likely to be susceptible to IPM
    • Subjects receiving antibiotic prophylaxis for UTI who present with signs and symptoms consistent with an active new UTI

Exclusion criteria

Exclusion Criteria:

  • Urine culture identifies only a Gram-positive pathogen and/or a Gram-negative uropathogen resistant to IPM
  • Urine culture at study entry isolates more than 2 uropathogens or patient has a confirmed fungal UTI
  • Asymptomatic bacteriuria, the presence of >10\^5 CFU/mL of a uropathogen and pyuria but without local or systemic symptoms
  • Patient is receiving hemodialysis or peritoneal dialysis
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
452 participants (actual)

Study arms

  • Experimental
    Cefiderocol

    Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.

    Drug: Cefiderocol

  • Active comparator
    Imipenem/cilastatin

    Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.

    Drug: Imipenem/cilastatin

Interventions

  • 2000 mg intravenously every 8 hours for 7 to 14 days; dose adjustments for participants with reduced renal function (estimated CrCl ≤ 70 mL/minute) and/or body weight (\< 70 kg) included every 6-hour dosing intervals and/or reduced doses.

    Also known as: FETROJA®, S-649266

  • DrugImipenem/cilastatin

    Drug pages: Imipenem · Cilastatin

    1000 mg of each intravenously every 8 hours for 7 to 14 days; dose adjustments for participants with reduced renal function (estimated CrCl ≤ 70 mL/minute) and/or body weight (\< 70 kg) included every 6-hour dosing intervals and/or reduced doses.

    Also known as: PRIMAXIN®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Test of Cure

    The primary efficacy endpoint was the composite outcome of clinical response and microbiological response at the test of cure assessment, defined as 7 days (±2 days) after the end of antibiotic treatment. Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.

    Time frame: Test of cure (TOC; 7 days after end of treatment [EOT], equivalent to Study Day 14 to 21)

Secondary outcomes

  1. Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Early Assessment

    A composite outcome of clinical response and microbiological response at the early assessment, defined as Day 4 of antibiotic treatment. Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.

    Time frame: Early assessment (EA; Day 4)

  2. Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at End of Treatment

    A composite outcome of clinical response and microbiological response at the end of treatment, defined as the end of the last infusion of antibiotic treatment. Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.

    Time frame: End of treatment (EOT; Day 7 to 14)

  3. Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Follow-up

    A composite response of clinical response and microbiological response at the follow-up assessment, defined as 14 days after the end of treatment. Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with sustained response defined as all pre-therapy signs and symptoms of cUTI show no evidence of recurrence after administration of the last dose of study drug. Microbiological outcome was based on quantitative microbiological urine cultures, with sustained eradication defined as a urine culture obtained after documented eradication at the TOC, up to and including the FUP, showed that the bacterial uropathogen(s) identified at baseline at ≥ 10⁵ CFU/mL remained \< 10⁴ CFU/mL.

    Time frame: Follow-up (FUP; 14 days after end of treatment, Day 21 to 28)

  4. Percentage of Participants With Microbiological Eradication at Test of Cure

    Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as all bacterial uropathogens found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.

    Time frame: Test of cure (7 days after end of treatment, Day 14 to 21)

  5. Percentage of Participants With Microbiological Eradication at Early Assessment

    Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as all bacterial uropathogens found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.

    Time frame: Early assessment, Day 4

  6. Percentage of Participants With Microbiological Eradication at End of Treatment

    Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as all bacterial uropathogens found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.

    Time frame: End of treatment, Day 7 to 14

  7. Percentage of Participants With Microbiological Eradication at Follow-up

    Microbiological outcome was based on quantitative microbiological urine cultures, with sustained eradication defined as a urine culture obtained after documented eradication at the TOC, up to and including the FUP, where the bacterial uropathogen(s) identified at baseline at ≥ 10⁵ CFU/mL remained \< 10⁴ CFU/mL.

    Time frame: Follow-up, 14 days after end of treatment, Day 21 to 28

  8. Percentage of Participants With Microbiological Eradication at Test of Cure Per Uropathogen

    Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.

    Time frame: Test of cure; 7 days after end of treatment, Day 14 to 21

  9. Percentage of Participants With Microbiological Eradication at Early Assessment Per Uropathogen

    Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.

    Time frame: Early assessment, Day 4

  10. Percentage of Participants With Microbiological Eradication at End of Treatment Per Uropathogen

    Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.

    Time frame: End of treatment, Day 7 to 14

  11. Percentage of Participants With Microbiological Eradication at Follow-up Per Uropathogen

    Microbiological outcome was based on quantitative microbiological urine cultures, with sustained eradication defined as a urine culture obtained after documented eradication at the TOC, up to and including the FUP, where the bacterial uropathogen identified at baseline at ≥ 10⁵ CFU/mL remained \< 10⁴ CFU/mL. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.

    Time frame: Follow-up, 14 days after the end of treatment, Day 21 to 28

  12. Percentage of Participants With Clinical Response at Test of Cure

    Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.

    Time frame: Test of cure, 7 days after end of treatment, Day 14 to 21

  13. Percentage of Participants With Clinical Response at Early Assessment

    Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.

    Time frame: Early assessment, Day 4

  14. Percentage of Participants With Clinical Response at End of Treatment

    Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.

    Time frame: End of treatment, Day 7 to 14

  15. Percentage of Participants With Clinical Response at Follow-up

    Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with sustained response defined as all pre-therapy signs and symptoms of cUTI showing no evidence of recurrence after administration of the last dose of study drug.

    Time frame: Follow-up, 14 days after end of treatment, Day 21 to 28

  16. Percentage of Participants With Clinical Response at Test of Cure Per Uropathogen

    Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.

    Time frame: Test of cure, 7 days after end of treatment, Day 14 to 21

  17. Percentage of Participants With Clinical Response at Early Assessment Per Uropathogen

    Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.

    Time frame: Early assessment, Day 4

  18. Percentage of Participants With Clinical Response at End of Treatment Per Uropathogen

    Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.

    Time frame: End of treatment, Day 7 to 14

  19. Percentage of Participants With Clinical Response at Follow-up Per Uropathogen

    Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with sustained response defined as all pre-therapy signs and symptoms of cUTI show no evidence of recurrence after administration of the last dose of study drug. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.

    Time frame: Follow-up, 14 days after the end of treatment, Day 21 to 28

  20. Plasma Concentration of Cefiderocol

    Time frame: On Day 3 of dosing prior to infusion, end of infusion, and at 1 hour post infusion

  21. Urine Concentration of Cefiderocol

    Time frame: Day 3, 2 hours and 6 hours after end of infusion

  22. Number of Participants With Adverse Events

    A serious adverse event was defined by regulation as any adverse event (AE) occurring at any dose that resulted in any of the following outcomes: * Death * Life-threatening condition * Hospitalization or prolongation of existing hospitalization * Persistent or significant disability/incapacity * Congenital anomaly/birth defect * Other medically important condition. The relationship of an event to the study drug was determined by the investigator based on whether the AE could be reasonably explained as being caused by the study drug.

    Time frame: From first dose of study drug until 28 days after end of treatment; Day 35 to 42

07

Results

Posted Dec 12, 2019

Participant flow

This study was conducted at 67 hospitals in 15 countries. Participants diagnosed with complicated urinary tract infections (cUTIs) with or without pyelonephritis or acute uncomplicated pyelonephritis were enrolled from February 5, 2015 to August 16, 2016.

Participant flow — Overall Study
MilestoneCefiderocolImipenem/Cilastatin
Started303149
Received study drug300148
Completed283138
Not completed2011
Withdrew: Withdrawal by subject33
Withdrew: Death10
Withdrew: Protocol violation10
Withdrew: Lost to follow-up104
Withdrew: Adverse event23
Withdrew: Other, miscellaneous31

Outcome measures

PrimaryPercentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Test of Cure

The primary efficacy endpoint was the composite outcome of clinical response and microbiological response at the test of cure assessment, defined as 7 days (±2 days) after the end of antibiotic treatment. Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.

Time frame:
Test of cure (TOC; 7 days after end of treatment [EOT], equivalent to Study Day 14 to 21)
Reported as:
Number · percentage of participants
Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Test of Cure
percentage of participantsCefiderocolImipenem/Cilastatin
Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Test of Cure72.654.6
Statistical analysis
  • Cefiderocol vs Imipenem/Cilastatin · Treatment difference: 18.58 · 95% CI 8.23 to 28.92
SecondaryPercentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Early Assessment

A composite outcome of clinical response and microbiological response at the early assessment, defined as Day 4 of antibiotic treatment. Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.

Time frame:
Early assessment (EA; Day 4)
Reported as:
Number · percentage of participants
Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Early Assessment
percentage of participantsCefiderocolImipenem/Cilastatin
Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Early Assessment88.187.4
Statistical analysis
  • Cefiderocol vs Imipenem/Cilastatin · Treatment difference: 0.66 · 95% CI -6.48 to 7.79
SecondaryPercentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at End of Treatment

A composite outcome of clinical response and microbiological response at the end of treatment, defined as the end of the last infusion of antibiotic treatment. Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.

Time frame:
End of treatment (EOT; Day 7 to 14)
Reported as:
Number · percentage of participants
Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at End of Treatment
percentage of participantsCefiderocolImipenem/Cilastatin
Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at End of Treatment96.495.8
Statistical analysis
  • Cefiderocol vs Imipenem/Cilastatin · Treatment difference: 0.72 · 95% CI -3.48 to 4.92
SecondaryPercentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Follow-up

A composite response of clinical response and microbiological response at the follow-up assessment, defined as 14 days after the end of treatment. Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with sustained response defined as all pre-therapy signs and symptoms of cUTI show no evidence of recurrence after administration of the last dose of study drug. Microbiological outcome was based on quantitative microbiological urine cultures, with sustained eradication defined as a urine culture obtained after documented eradication at the TOC, up to and including the FUP, showed that the bacterial uropathogen(s) identified at baseline at ≥ 10⁵ CFU/mL remained \< 10⁴ CFU/mL.

Time frame:
Follow-up (FUP; 14 days after end of treatment, Day 21 to 28)
Reported as:
Number · percentage of participants
Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Follow-up
percentage of participantsCefiderocolImipenem/Cilastatin
Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Follow-up54.439.5
Statistical analysis
  • Cefiderocol vs Imipenem/Cilastatin · Treatment difference: 15.31 · 95% CI 4.69 to 25.92
SecondaryPercentage of Participants With Microbiological Eradication at Test of Cure

Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as all bacterial uropathogens found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.

Time frame:
Test of cure (7 days after end of treatment, Day 14 to 21)
Reported as:
Number · percentage of participants
Percentage of Participants With Microbiological Eradication at Test of Cure
percentage of participantsCefiderocolImipenem/Cilastatin
Percentage of Participants With Microbiological Eradication at Test of Cure73.056.3
Statistical analysis
  • Cefiderocol vs Imipenem/Cilastatin · Treatment difference: 17.25 · 95% CI 6.92 to 27.58
SecondaryPercentage of Participants With Microbiological Eradication at Early Assessment

Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as all bacterial uropathogens found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.

Time frame:
Early assessment, Day 4
Reported as:
Number · percentage of participants
Percentage of Participants With Microbiological Eradication at Early Assessment
percentage of participantsCefiderocolImipenem/Cilastatin
Percentage of Participants With Microbiological Eradication at Early Assessment92.190.8
Statistical analysis
  • Cefiderocol vs Imipenem/Cilastatin · Treatment difference: 1.28 · 95% CI -4.83 to 7.39
SecondaryPercentage of Participants With Microbiological Eradication at End of Treatment

Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as all bacterial uropathogens found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.

Time frame:
End of treatment, Day 7 to 14
Reported as:
Number · percentage of participants
Percentage of Participants With Microbiological Eradication at End of Treatment
percentage of participantsCefiderocolImipenem/Cilastatin
Percentage of Participants With Microbiological Eradication at End of Treatment96.895.8
Statistical analysis
  • Cefiderocol vs Imipenem/Cilastatin · Treatment difference: 1.10 · 95% CI -3.04 to 5.25
SecondaryPercentage of Participants With Microbiological Eradication at Follow-up

Microbiological outcome was based on quantitative microbiological urine cultures, with sustained eradication defined as a urine culture obtained after documented eradication at the TOC, up to and including the FUP, where the bacterial uropathogen(s) identified at baseline at ≥ 10⁵ CFU/mL remained \< 10⁴ CFU/mL.

Time frame:
Follow-up, 14 days after end of treatment, Day 21 to 28
Reported as:
Number · percentage of participants
Percentage of Participants With Microbiological Eradication at Follow-up
percentage of participantsCefiderocolImipenem/Cilastatin
Percentage of Participants With Microbiological Eradication at Follow-up57.143.7
Statistical analysis
  • Cefiderocol vs Imipenem/Cilastatin · Treatment difference: 13.92 · 95% CI 3.21 to 24.63
SecondaryPercentage of Participants With Microbiological Eradication at Test of Cure Per Uropathogen

Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.

Time frame:
Test of cure; 7 days after end of treatment, Day 14 to 21
Reported as:
Number · percentage of participants
Percentage of Participants With Microbiological Eradication at Test of Cure Per Uropathogen
percentage of participantsCefiderocolImipenem/Cilastatin
Escherichia coli75.058.2
Klebsiella pneumoniae75.052.0
Pseudomonas aeruginosa44.460.0
Proteus mirabilis76.550.0
SecondaryPercentage of Participants With Microbiological Eradication at Early Assessment Per Uropathogen

Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.

Time frame:
Early assessment, Day 4
Reported as:
Number · percentage of participants
Percentage of Participants With Microbiological Eradication at Early Assessment Per Uropathogen
percentage of participantsCefiderocolImipenem/Cilastatin
Escherichia coli92.894.9
Klebsiella pneumoniae89.688.0
Pseudomonas aeruginosa94.480.0
Proteus mirabilis88.2100.0
SecondaryPercentage of Participants With Microbiological Eradication at End of Treatment Per Uropathogen

Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at \> 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.

Time frame:
End of treatment, Day 7 to 14
Reported as:
Number · percentage of participants
Percentage of Participants With Microbiological Eradication at End of Treatment Per Uropathogen
percentage of participantsCefiderocolImipenem/Cilastatin
Escherichia coli98.797.5
Klebsiella pneumoniae97.992.0
Pseudomonas aeruginosa88.9100.0
Proteus mirabilis94.1100.0
SecondaryPercentage of Participants With Microbiological Eradication at Follow-up Per Uropathogen

Microbiological outcome was based on quantitative microbiological urine cultures, with sustained eradication defined as a urine culture obtained after documented eradication at the TOC, up to and including the FUP, where the bacterial uropathogen identified at baseline at ≥ 10⁵ CFU/mL remained \< 10⁴ CFU/mL. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.

Time frame:
Follow-up, 14 days after the end of treatment, Day 21 to 28
Reported as:
Number · percentage of participants
Percentage of Participants With Microbiological Eradication at Follow-up Per Uropathogen
percentage of participantsCefiderocolImipenem/Cilastatin
Escherichia coli59.941.8
Klebsiella pneumoniae58.352.0
Pseudomonas aeruginosa27.820.0
Proteus mirabilis64.70
SecondaryPercentage of Participants With Clinical Response at Test of Cure

Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.

Time frame:
Test of cure, 7 days after end of treatment, Day 14 to 21
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Response at Test of Cure
percentage of participantsCefiderocolImipenem/Cilastatin
Percentage of Participants With Clinical Response at Test of Cure89.787.4
Statistical analysis
  • Cefiderocol vs Imipenem/Cilastatin · Treatment difference: 2.39 · 95% CI -4.66 to 9.44
SecondaryPercentage of Participants With Clinical Response at Early Assessment

Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.

Time frame:
Early assessment, Day 4
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Response at Early Assessment
percentage of participantsCefiderocolImipenem/Cilastatin
Percentage of Participants With Clinical Response at Early Assessment90.590.8
Statistical analysis
  • Cefiderocol vs Imipenem/Cilastatin · Treatment difference: -0.26 · 95% CI -6.57 to 6.05
SecondaryPercentage of Participants With Clinical Response at End of Treatment

Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.

Time frame:
End of treatment, Day 7 to 14
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Response at End of Treatment
percentage of participantsCefiderocolImipenem/Cilastatin
Percentage of Participants With Clinical Response at End of Treatment98.099.2
Statistical analysis
  • Cefiderocol vs Imipenem/Cilastatin · Treatment difference: -1.07 · 95% CI -3.42 to 1.29
SecondaryPercentage of Participants With Clinical Response at Follow-up

Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with sustained response defined as all pre-therapy signs and symptoms of cUTI showing no evidence of recurrence after administration of the last dose of study drug.

Time frame:
Follow-up, 14 days after end of treatment, Day 21 to 28
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Response at Follow-up
percentage of participantsCefiderocolImipenem/Cilastatin
Percentage of Participants With Clinical Response at Follow-up81.372.3
Statistical analysis
  • Cefiderocol vs Imipenem/Cilastatin · Treatment difference: 9.02 · 95% CI -0.37 to 18.41
SecondaryPercentage of Participants With Clinical Response at Test of Cure Per Uropathogen

Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.

Time frame:
Test of cure, 7 days after end of treatment, Day 14 to 21
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Response at Test of Cure Per Uropathogen
percentage of participantsCefiderocolImipenem/Cilastatin
Escherichia coli89.788.3
Klebsiella pneumoniae89.184.0
Pseudomonas aeruginosa73.375.0
Proteus mirabilis100.0100.0
SecondaryPercentage of Participants With Clinical Response at Early Assessment Per Uropathogen

Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.

Time frame:
Early assessment, Day 4
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Response at Early Assessment Per Uropathogen
percentage of participantsCefiderocolImipenem/Cilastatin
Escherichia coli91.896.1
Klebsiella pneumoniae82.688.0
Pseudomonas aeruginosa93.375.0
Proteus mirabilis84.6100.0
SecondaryPercentage of Participants With Clinical Response at End of Treatment Per Uropathogen

Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.

Time frame:
End of treatment, Day 7 to 14
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Response at End of Treatment Per Uropathogen
percentage of participantsCefiderocolImipenem/Cilastatin
Escherichia coli97.998.7
Klebsiella pneumoniae100.0100.0
Pseudomonas aeruginosa93.3100.0
Proteus mirabilis100.0100.0
SecondaryPercentage of Participants With Clinical Response at Follow-up Per Uropathogen

Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with sustained response defined as all pre-therapy signs and symptoms of cUTI show no evidence of recurrence after administration of the last dose of study drug. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.

Time frame:
Follow-up, 14 days after the end of treatment, Day 21 to 28
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Response at Follow-up Per Uropathogen
percentage of participantsCefiderocolImipenem/Cilastatin
Escherichia coli82.972.7
Klebsiella pneumoniae82.668.0
Pseudomonas aeruginosa53.375.0
Proteus mirabilis84.6100.0
SecondaryPlasma Concentration of Cefiderocol
Time frame:
On Day 3 of dosing prior to infusion, end of infusion, and at 1 hour post infusion
Reported as:
Mean · µg/mL
Plasma Concentration of Cefiderocol
µg/mLCefiderocol
Pre-infusion18.0 ± 18.3
End of infusion141 ± 220
1 hour after end of infusion70.2 ± 30.4
SecondaryUrine Concentration of Cefiderocol
Time frame:
Day 3, 2 hours and 6 hours after end of infusion
Reported as:
Mean · µg/mL
Urine Concentration of Cefiderocol
µg/mLCefiderocol
2 hours after end of infusion2710 ± 1520
6 hours after end of infusion1520 ± 1370
SecondaryNumber of Participants With Adverse Events

A serious adverse event was defined by regulation as any adverse event (AE) occurring at any dose that resulted in any of the following outcomes: * Death * Life-threatening condition * Hospitalization or prolongation of existing hospitalization * Persistent or significant disability/incapacity * Congenital anomaly/birth defect * Other medically important condition. The relationship of an event to the study drug was determined by the investigator based on whether the AE could be reasonably explained as being caused by the study drug.

Time frame:
From first dose of study drug until 28 days after end of treatment; Day 35 to 42
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsCefiderocolImipenem/Cilastatin
All adverse events12276
Drug-related adverse events2717
Deaths10
Serious adverse events1412
Drug-related serious adverse events11
Discontinuation of study drug due to AE53
Discontinuation due to drug-related AE30

Adverse events

Collected over From first dose of study drug until 28 days after end of treatment; Day 35 to 42. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
S-6492661/300 (0.3%)14/300 (4.7%)60/300 (20%)
Imipenem/Cilastatin0/148 (0%)12/148 (8.1%)48/148 (32.4%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventS-649266Imipenem/Cilastatin
Clostridium difficile colitisInfections and infestations1/3002/148
Cardiac failureCardiac disorders1/3001/148
Congenital ureteric anomalyCongenital, familial and genetic disorders0/3001/148
DiarrhoeaGastrointestinal disorders1/3001/148
Lower gastrointestinal haemorrhageGastrointestinal disorders0/3001/148
AbscessInfections and infestations0/3001/148
Device related infectionInfections and infestations0/3001/148
Prostatic abscessInfections and infestations0/3001/148
PyelonephritisInfections and infestations0/3001/148
Alcohol poisoningInjury, poisoning and procedural complications0/3001/148
Most frequent other events
Showing 10 of 15
Most frequent other events
EventS-649266Imipenem/Cilastatin
DiarrhoeaGastrointestinal disorders12/3008/148
HeadacheNervous system disorders7/3008/148
HypertensionVascular disorders13/3008/148
ConstipationGastrointestinal disorders10/3006/148
NauseaGastrointestinal disorders7/3006/148
Abdominal pain upperGastrointestinal disorders2/3005/148
Infusion site painGeneral disorders9/3005/148
Renal cystRenal and urinary disorders4/3005/148
HypokalaemiaMetabolism and nutrition disorders5/3004/148
CoughRespiratory, thoracic and mediastinal disorders7/3001/148

Baseline characteristics

Modified intent-to-treat population includes all randomly assigned participants who received at least one dose of study drug and had qualifying Gram-negative uropathogen (≥1 × 10⁵ colony forming unit (CFU)/mL)

Age, Continuous
Age, Continuous(years)CefiderocolImipenem/CilastatinTotal
Mean62.3 ± 16.1061.3 ± 18.4862.0 ± 16.88
Age, Customized
Age, Customized(Participants)CefiderocolImipenem/CilastatinTotal
< 65 years11354167
>= 65 years13965204
Sex: Female, Male
Sex: Female, Male(Participants)CefiderocolImipenem/CilastatinTotal
Female13371204
Male11948167
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CefiderocolImipenem/CilastatinTotal
Hispanic or Latino516
Not Hispanic or Latino247118365
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)CefiderocolImipenem/CilastatinTotal
White241115356
Black or African American101
Asian9413
Native Hawaiian or Other Pacific Islander101
Creatinine Clearance Renal Grading Group
Creatinine Clearance Renal Grading Group(Participants)CefiderocolImipenem/CilastatinTotal
> 80 mL/min (Normal)12451175
> 50 - 80 mL/min (Mild)7841119
30 - 50 mL/min (Moderate)412364
< 30 mL/min (Severe)7411
Clinical Diagnosis at Baseline
Clinical Diagnosis at Baseline(Participants)CefiderocolImipenem/CilastatinTotal
cUTI with pyelonephritis652994
cUTI without pyelonephritis12255177
Acute Uncomplicated Pyelonephritis6535100
Number of Gram-negative Uropathogens > 10⁵ CFU/mL Isolated at Baseline
Number of Gram-negative Uropathogens > 10⁵ CFU/mL Isolated at Baseline(Participants)CefiderocolImipenem/CilastatinTotal
1 uropathogen241115356
2 uropathogens11415
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JCA, Ariyasu M, Tenke P, Nagata TD. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018 Dec;18(12):1319-1328. doi: 10.1016/S1473-3099(18)30554-1. Epub 2018 Oct 25. PubMed 30509675 ↗
  • Portsmouth S, Echols R, Toyoizumi K, Tillotson G, Nagata TD. Structured patient interview to assess clinical outcomes in complicated urinary tract infections in the APEKS-cUTI study: pilot investigation. Ther Adv Infect Dis. 2021 Nov 24;8:20499361211058257. doi: 10.1177/20499361211058257. eCollection 2021 Jan-Dec. PubMed 34868583 ↗
  • Wenzler E, Butler D, Tan X, Katsube T, Wajima T. Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy. Clin Pharmacokinet. 2022 Apr;61(4):539-552. doi: 10.1007/s40262-021-01086-y. Epub 2021 Nov 18. Erratum In: Clin Pharmacokinet. 2022 Jul;61(7):1069. doi: 10.1007/s40262-022-01146-x. PubMed 34792787 ↗
  • Naseer S, Weinstein EA, Rubin DB, Suvarna K, Wei X, Higgins K, Goodwin A, Jang SH, Iarikov D, Farley J, Nambiar S. US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja(R)). Clin Infect Dis. 2021 Jun 15;72(12):e1103-e1111. doi: 10.1093/cid/ciaa1799. PubMed 33393598 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2015 to primary completion in Jul 2016, 17 months.

Results were first posted in Dec 2019, 3 years 4 months after primary completion. A results delay was requested in Jul 2017.

Of 30 phase 2 interventional studies under Urinary Tract Infections, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 38. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2014
First posted
Dec 22, 2014
StartActual
Feb 5, 2015
Primary completionActual
Jul 26, 2016
CompletionActual
Aug 16, 2016
Results delay requested
Jul 11, 2017
Results first posted
Dec 12, 2019
Last update
Dec 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02321800
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Dec 22, 2014
Start date
Feb 5, 2015
Primary completion
Jul 26, 2016
Completion
Aug 16, 2016
Results posted
Dec 12, 2019
Last update
Dec 12, 2019

Study contacts

Shionogi Clinical Trials Administrator Clinical Support Help Line
study director · Shionogi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cefiderocol

Start the discussion